Raptor Pharmaceutical Corp

Novato, Jan. 11 / PRNewswire-PR Newswire / - Raptor Pharmaceutical Corp. (Hereinafter referred to as "Raptor" or the "Company") today announced its used to treat nephrotic cystinosis (referred to as "bladder histidine disease ") in patients with a proprietary sustained-release cysteamine bitartrate (referred to as" DR Cysteamine ") prototype formulation phase 2a clinical outcome. San Diego University of California (University of California) pediatrics expert Ranjan Dohil, MD, is the main sponsor of this study, the study in the United States, "Pediatrics" (Journal of Pediatrics) published, but also through http://www .ncbi.nlm.nih.gov/pubmed/19775699? itool = EntrezSystem2.PEntrez.Pubmed. Pubmed_ResultsPanel.Pubmed_RVDocSum & ordinalpos = 1 web.
(Icon: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO)

The Phase 2a study demonstrated for DR Cysteamine theory test, DR Cysteamine is the immediate release cysteamine bitartrate capsules gelatin beads Raptor's proprietary enteric release formulations. Immediate-release cysteamine bitartrate (referred to as "IR Cysteamine") is used for the treatment of cystinosis current standards. This result shows that DR Cysteamine twice daily doses, its DR Cysteamine in cystinosis prototype formulations can effectively maintain low levels of white blood cells (WBC) cystine (2.5 nmol cystine / 1 mg protein). The results also showed that if patients taking doses of DR Cysteamine in the original IR Cysteamine simply served on about 60% of the total dose, DR Cysteamine prototype equipped with convenient trough WBC cystine levels can be maintained at a satisfactory range.
Dohil said: "Because IR Cysteamine has been writing letters to patients cystine, causing poor treatment adherence to its extensive coverage of events, so we're looking to improve IR Cysteamine resistance and reduce their dosage requirements new drugs and we believe this will further promote the Phase 2a study of patients seeking cystine potential therapeutic solutions to our clinical trial results show that this release cysteamine drug formulation taken twice a day and its total daily doses doses lower than IR Cysteamine, can improve drug resistance and efficacy. Based on these results, I believe that Raptor's DR Cysteamine final formulation with improved patient Zheyi from cystine and its potential for long-term treatment. "